(19)
(11) EP 1 685 839 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.06.2013 Bulletin 2013/26

(45) Mention of the grant of the patent:
10.04.2013 Bulletin 2013/15

(21) Application number: 06111805.5

(22) Date of filing: 22.12.1998
(51) International Patent Classification (IPC): 
A61K 31/485(2006.01)
 A61P 25/36(2006.01)

(54)

Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist

Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem Opioid-Agonisten und einem Opioid- Antagonisten

Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste et un antagoniste des récepteurs opiacés

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.12.1997 US 68480 P

(43) Date of publication of application:
02.08.2006 Bulletin 2006/31

(60) Divisional application:
10179026.9 / 2266564

(62) Application number of the earlier application in accordance with Art. 76 EPC:
98964853.0 / 1041987

(73) Proprietor: EURO-CELTIQUE S.A.
1653 Luxembourg (LU)

(72) Inventors:
  • Kaiko, Robert F.
    Weston, CT 06883 (US)
  • Colucci, Robert D.
    Newtown, CT 06482 (US)

(74) Representative: Glas, Holger 
Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3
80335 München
80335 München (DE)


(56) References cited: : 
WO-A-97/33566
US-A- 4 582 835
US-A- 5 512 578
 US-A- 4 457 933
US-A- 4 661 492
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).